Last reviewed · How we verify
SL1002
SL1002 is a recombinant human serum albumin-interferon alpha fusion protein that enhances innate immune responses against viral infections and cancer.
SL1002 is a recombinant human serum albumin-interferon alpha fusion protein that enhances innate immune responses against viral infections and cancer. Used for Chronic hepatitis C virus infection, Melanoma.
At a glance
| Generic name | SL1002 |
|---|---|
| Sponsor | Saol Therapeutics Inc |
| Drug class | Interferon alpha fusion protein |
| Target | Interferon alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Virology, Immunology |
| Phase | Phase 3 |
Mechanism of action
SL1002 combines human serum albumin with interferon alpha to improve the pharmacokinetic properties and bioavailability of interferon while maintaining its immunostimulatory effects. The fusion protein activates natural killer cells and other components of the innate immune system, making it suitable for treating conditions where enhanced interferon signaling is therapeutically beneficial.
Approved indications
- Chronic hepatitis C virus infection
- Melanoma
Common side effects
- Flu-like symptoms
- Fatigue
- Fever
- Myalgia
- Headache
Key clinical trials
- Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain (PHASE3)
- Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity (PHASE2)
- Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |